{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:49:16Z","timestamp":1782218956762,"version":"3.54.5"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874044"],"award-info":[{"award-number":["81874044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.critrevonc.2022.103760","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T22:32:38Z","timestamp":1658356358000},"page":"103760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"177","author":[{"given":"Fei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wengang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.critrevonc.2022.103760_bib1","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103760_bib2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J. Comput. Graph. Stat."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103760_bib3","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jtho.2016.12.014","article-title":"Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer","volume":"12","author":"Castellanos","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103760_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"27","key":"10.1016\/j.critrevonc.2022.103760_bib5","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1200\/JCO.2016.66.9218","article-title":"Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations","volume":"34","author":"Cheng","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103760_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study","volume":"16","author":"Cheng","year":"2021","journal-title":"Target Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103760_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtho.2018.09.004","article-title":"Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset","volume":"14","author":"Cho","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103760_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103760_bib9","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"7\u20138","key":"10.1016\/j.critrevonc.2022.103760_bib10","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103760_bib11","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.21037\/jtd.2019.09.19","article-title":"Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer","volume":"11","author":"Gao","year":"2019","journal-title":"J. Thorac. Dis."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103760_bib12","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1016\/j.jtho.2018.08.290","article-title":"Afatinib with or without cetuximab for EGFR-mutant non-small cell lung cancer: safety and efficacy results from SWOG S1403","volume":"13","author":"Goldberg","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103760_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5858\/arpa.2016-0579-CP","article-title":"Worldwide frequency of commonly detected EGFR mutations","volume":"142","author":"Graham","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103760_bib14","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ijc.30806","article-title":"Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial","volume":"141","author":"Han","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103760_bib15","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.21037\/tlcr-20-1153","article-title":"Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer-an option for overcoming EGFR-TKI resistance","volume":"10","author":"Han","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103760_bib16","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update","volume":"39","author":"Hanna","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103760_bib17","first-page":"393","article-title":"Sex disparities matter in cancer development and therapy","volume":"21","author":"Haupt","year":"2021"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103760_bib18","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/annonc\/mdw271","article-title":"Chemotherapy remains an essential element of personalized care for persons with lung cancers","volume":"27","author":"Hellmann","year":"2016","journal-title":"Ann. Oncol."},{"issue":"7689","key":"10.1016\/j.critrevonc.2022.103760_bib19","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"issue":"7414","key":"10.1016\/j.critrevonc.2022.103760_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103760_bib21","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaoncol.2018.0049","article-title":"Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients With EGFR-Mutant advanced non-small cell lung cancer","volume":"4","author":"Hong","year":"2018","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103760_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103760_bib23","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103760_bib24","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/1535-7163.MCT-15-0582","article-title":"Bevacizumab prevents brain metastases formation in lung adenocarcinoma","volume":"15","author":"Ilhan-Mutlu","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103760_bib25","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jtho.2017.05.018","article-title":"A higher proportion of the EGFR T790M mutation may contribute to the better survival of patients with exon 19 deletions compared with those with L858R","volume":"12","author":"Ke","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2022.103760_bib26","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","article-title":"Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial","volume":"19","author":"Kelly","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103760_bib27","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.jtho.2016.06.002","article-title":"International Association for the Study of Lung Cancer Advanced Radiation Technology. brain metastases from NSCLC: radiation therapy in the era of targeted therapies","volume":"11","author":"Khalifa","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103760_bib28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103760_bib29","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jtho.2016.03.006","article-title":"Combination of gefitinib and pemetrexed prevents the acquisition of TKI Resistance in NSCLC cell lines carrying EGFR-activating mutation","volume":"11","author":"La Monica","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl 15","key":"10.1016\/j.critrevonc.2022.103760_bib30","doi-asserted-by":"crossref","first-page":"S1831","DOI":"10.21037\/jtd.2019.08.104","article-title":"Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer","volume":"11","author":"Lamberti","year":"2019","journal-title":"J. Thorac. Dis."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103760_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw279","article-title":"Gefitinib or Erlotinib vs Chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival","volume":"109","author":"Lee","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103760_bib32","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.18632\/oncotarget.13787","article-title":"The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2022.103760_bib33","first-page":"9013","article-title":"Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm)","author":"Lu","year":"2021","journal-title":"ASCO"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103760_bib34","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/JTO.0b013e318260de8b","article-title":"First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study","volume":"7","author":"Maemondo","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103760_bib35","first-page":"121","article-title":"Cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"trial"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103760_bib36","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/jjco\/hyv054","article-title":"Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-Data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)","volume":"45","author":"Miyauchi","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103760_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cells7110212","article-title":"Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy","volume":"7","author":"Nagano","year":"2018","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103760_bib38","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jtho.2020.11.028","article-title":"Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC","volume":"16","author":"Nagasaka","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103760_bib39","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103760_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115065","article-title":"Network meta-analysis using R: a review of currently available automated packages","volume":"9","author":"Neupane","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103760_bib41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.19.01154","article-title":"Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer","volume":"38","author":"Noronha","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103760_bib42","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/annonc\/mdl377","article-title":"Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan","volume":"18","author":"Ohe","year":"2007","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103760_bib43","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103760_bib44","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103760_bib45","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1001\/jamaoncol.2020.4232","article-title":"Association of survival with adjuvant chemotherapy among patients with early-stage non-small cell lung cancer with vs without high-risk clinicopathologic features","volume":"6","author":"Pathak","year":"2020","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103760_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000344","article-title":"Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy","volume":"3","author":"Pinto","year":"2018","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103760_bib47","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jtho.2018.12.021","article-title":"FGFR1 cooperates with EGFR in lung cancer oncogenesis, and their combined inhibition shows improved efficacy","volume":"14","author":"Quintanal-Villalonga","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"3 Pt 1","key":"10.1016\/j.critrevonc.2022.103760_bib48","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","article-title":"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib","volume":"12","author":"Riely","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103760_bib49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103760_bib50","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103760_bib51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"21","key":"10.1016\/j.critrevonc.2022.103760_bib52","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"75","key":"10.1016\/j.critrevonc.2022.103760_bib53","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"27","key":"10.1016\/j.critrevonc.2022.103760_bib54","first-page":"3327","volume":"31","author":"Sequist","year":"2013","journal-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103760_bib55","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103760_bib56","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103760_bib57","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1988.6.9.1474","article-title":"Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis","volume":"6","author":"Sorensen","year":"1988","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103760_bib58","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103760_bib59","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103760_bib60","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jamaoncol.2019.1847","article-title":"Effect of erlotinib plus Bevacizumab vs Erlotinib alone on progression-free survival in patients with advanced egfr-mutant non-small cell lung cancer: a phase 2 randomized clinical trial","volume":"5","author":"Stinchcombe","year":"2019","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103760_bib61","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103760_bib62","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103760_bib63","doi-asserted-by":"crossref","first-page":"13574","DOI":"10.1038\/srep13574","article-title":"EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway","volume":"5","author":"Tsai","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103760_bib64","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.critrevonc.2022.103760_bib65","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2018.05.014","article-title":"Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: a meta-analysis","volume":"122","author":"Wang","year":"2018","journal-title":"Lung Cancer"},{"issue":"suppl_1","key":"10.1016\/j.critrevonc.2022.103760_bib66","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2022.103760_bib67","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.2217\/fon-2021-0218","article-title":"Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations","volume":"17","author":"Winfree","year":"2021","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103760_bib68","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3892\/mmr.2014.2243","article-title":"Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer","volume":"10","author":"Wu","year":"2014","journal-title":"Mol. Med Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103760_bib69","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00092-2016","article-title":"adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors","volume":"3","author":"Wu","year":"2017","journal-title":"ERJ Open Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103760_bib70","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103760_bib71","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103760_bib72","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.lungcan.2016.11.022","article-title":"Efficacy according to blind independent central review: post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin\/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC","volume":"104","author":"Wu","year":"2017","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103760_bib73","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.critrevonc.2022.103760_bib74","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients With T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III Trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103760_bib75","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/1759-7714.13533","article-title":"Tobacco extracts promote PD-L1 expression and enhance malignant biological differences via mTOR in gefitinib-resistant cell lines","volume":"11","author":"Xiao","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103760_bib76","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9311875","article-title":"Front-line therapy in EGFR exon 19 Deletion and 21 Leu858Arg mutations in advanced non-small cell lung cancer: a network meta-analysis","volume":"2021","author":"Xie","year":"2021","journal-title":"Evid. Based Complement Altern. Med."},{"key":"10.1016\/j.critrevonc.2022.103760_bib77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2019.05.008","article-title":"Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: a randomized controlled study","volume":"133","author":"Xu","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103760_bib78","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41467-020-15679-x","article-title":"Sex-associated molecular differences for cancer immunotherapy","volume":"11","author":"Ye","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103760_bib79","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl. Lung Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103760_bib80","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cllc.2014.09.008","article-title":"Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis","volume":"16","author":"Zhang","year":"2015","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103760_bib81","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40880-019-0414-4","article-title":"The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706","volume":"39","author":"Zhang","year":"2019","journal-title":"Cancer Commun. (Lond.)"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103760_bib82","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/ijc.31097","article-title":"Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer","volume":"142","author":"Zhao","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103760_bib83","doi-asserted-by":"crossref","first-page":"l5460","DOI":"10.1136\/bmj.l5460","article-title":"Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis","volume":"367","author":"Zhao","year":"2019","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103760_bib84","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/annonc\/mdv276","article-title":"Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802","volume":"26","author":"Zhou","year":"2015","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103760_bib85","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103760_bib86","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5732\/cjc.011.10106","article-title":"East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians","volume":"30","author":"Zhou","year":"2011","journal-title":"Chin. J. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822001846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822001846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:43:30Z","timestamp":1760903010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822001846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":86,"alternative-id":["S1040842822001846"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103760","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103760"}}